Clovis Oncology Inc. Daily Stock Analysis

Daily Stock Analysis, CLVS, Clovis Oncology Inc, priceseries

Clovis Oncology Inc. Daily Stock Analysis
Stock Information
Open
1.52
Close
1.50
High
1.57
Low
1.45
Previous Close
1.52
Daily Price Gain
-0.02
YTD High
3.14
YTD High Date
Jan 3, 2022
YTD Low
1.45
YTD Low Date
Mar 7, 2022
YTD Price Change
-1.64
YTD Gain
-52.23%
52 Week High
8.95
52 Week High Date
Mar 19, 2021
52 Week Low
1.45
52 Week Low Date
Mar 7, 2022
52 Week Price Change
-3.92
52 Week Gain
-72.32%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Dec 16. 2016
37.20
Jan 3. 2017
41.87
10 Trading Days
12.56%
Link
LONG
Jan 4. 2017
44.67
Feb 6. 2017
60.90
22 Trading Days
36.34%
Link
LONG
Sep 27. 2017
76.86
Oct 17. 2017
82.80
14 Trading Days
7.72%
Link
LONG
Nov 28. 2018
16.87
Dec 14. 2018
19.11
11 Trading Days
13.28%
Link
LONG
Jan 23. 2019
23.04
Feb 11. 2019
24.45
13 Trading Days
6.14%
Link
LONG
Nov 7. 2019
4.32
Dec 5. 2019
10.76
19 Trading Days
149.03%
Link
LONG
Apr 2. 2020
6.07
Apr 27. 2020
8.46
16 Trading Days
39.32%
Link
LONG
Sep 9. 2020
5.42
Sep 23. 2020
6.52
10 Trading Days
20.30%
Link
LONG
Nov 24. 2020
4.39
Dec 9. 2020
4.82
10 Trading Days
9.76%
Link
LONG
Jan 7. 2021
4.98
Feb 11. 2021
8.60
24 Trading Days
72.72%
Link
LONG
Jun 4. 2021
5.36
Jun 16. 2021
5.64
8 Trading Days
5.18%
Link
Company Information
Stock Symbol
CLVS
Exchange
NasdaqGS
Company URL
http://www.clovisoncology.com
Company Phone
(303) 625-5000
CEO
Patrick J. Mahaffy
Headquarters
Colorado
Business Address
5500 FLATIRON PARKWAY, SUITE 100, BOULDER, CO 80301
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001466301
About

Clovis Oncology, Inc. is a biopharmaceutical company which focuses on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. The company has three product candidates in its clinical development pipeline: Rociletinib, Rucaparib and Lucitani. Clovis Oncology was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.

Description

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, an oral and small molecule poly ADP-ribose polymerase inhibitor as monotherapy for the treatment of patients with deleterious breast cancer mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. The company is also involved in the ARIEL3 and ARIEL4 confirmatory trials of rucaparib as a potential maintenance therapy and treatment for ovarian cancer; trial of rucaparib in prostate indications (TRITON) 2, a Phase 2 single-arm study in men with metastatic castrate-resistant prostate cancer; and TRITON3, a Phase 3 comparative study in men with mCRPC enrolling BRCA mutant and ATM, as well as engages in the various clinical studies for other indications. It distributes its product primarily through specialty distributors and pharmacy providers to patients and health care providers. The company has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and Celgene Corporation; and collaboration and license agreement with Les Laboratoires Servier. Clovis Oncology, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading